GlassScriptPhysician profile
Edward A Kelly
NPI 1235122300
$8,542.34
in general payments reported to CMS, 2019-2025
46 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $635 · 2021: $1,283 · 2022: $1,466 · 2023: $1,245 · 2024: $1,250 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,753.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,263.44 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,253.04 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $798.21 | 2019-2025 | |
| Novo Nordisk INC | $711.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $638.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $631.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $348.10 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.53 | 2019-2025 | Jardiance, Trijardy Xr, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.77 | 2022-2025 | Caplyta |
| Allergan, INC. | $170.51 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $155.08 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $151.42 | 2019-2025 | Zoryve |
| Corium, LLC | $151.41 | 2022-2023 | Azstarys |
| Astellas Pharma US INC | $138.06 | 2024-2025 | Veozah |
| Abbott Laboratories | $130.38 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.